David (Wei Fu) Li

Davis Polk advised the underwriters in connection with the $55 million initial public offering of 3,666,667 shares of common stock of Ayala Pharmaceuticals, Inc. Ayala is traded on the…

Davis Polk advised ADC Therapeutics SA in connection with its entry into a facility agreement with Deerfield Partners, L.P., pursuant to which Deerfield agreed to extend senior secured…

Davis Polk advised the representatives of the several underwriters, in connection with an SEC-registered offering by Snap-on Incorporated of $500 million aggregate principal amount of its 3…

Davis Polk advised the representative of the initial purchasers in connection with a Rule 144A/Regulation S offering of $850 million aggregate principal amount of 6.250% senior notes due…

Davis Polk advised FedEx Corporation on its SEC-registered offering of $1 billion principal amount of 3.800% notes due 2025, $750 million principal amount of 4.250% notes due 2030 and $1.25…

Davis Polk advised Visa Inc. on its SEC-registered offering of $1.5 billion of 1.900% senior notes due 2027, $1.5 billion of 2.050% senior notes due 2030 and $1.0 billion of 2.700% senior…

Davis Polk advised the underwriters in connection with the offering of $2 billion aggregate principal amount of 1.375% U.S. dollar bonds due 2023 issued by Export Development Canada. Export…

Davis Polk advised the representatives of the several underwriters in connection with the SEC-registered offering of 6,500,000 shares of common stock of Applied Genetic Technologies…

Davis Polk advised the underwriters in connection with the offering of $2.25 billion aggregate principal amount of 1.875% bonds due November 13, 2024, issued by the Province of Alberta. The…

Davis Polk advised the underwriter in connection with the SEC-registered offering by PTC Therapeutics, Inc. of 2,475,248 shares of its common stock and the initial purchaser in a concurrent…